cartherics pty ltd logo

Cartherics Pty Ltd

Cartherics Pty Ltd is developing next generation immunotherapies for adenocarcinomas, with an initial primary focus on ovarian, gastric cancers and cutaneous T cell lymphomas. The products in development include potential chimeric antigen receptor (CAR-T) enhanced killer T cells for autologous and allogeneic (Çoff-the-shelf) cancer therapies.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://cartherics.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Level 7 Monash Health Translation Precinct Hudson Institute of Medical Research 27-31 Wright Street,VIC 3168
Clayton
Australia
Email
Contact Number
+61 3 8572 2500

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/cartherics-pty-ltd” connections=”true” suffix=””]

Cartherics use three unique proprietary approaches to produce individual CAR-T products for cancer patients.
(1) Development of CAR-T cells expressing two or more receptors specific for cancer cells to avoid the cancer escaping recognition.
(2). Access to carefully selected homozygous human leukocyte antigen (HLA) haplotyped _super donorsÓ for the production of induced pluripotent stem cells (iPSCs) to form the basis for CAR-T cells that will be compatible with the most common HLA types in Western and Asian communities and thereby provide _off-the-shelfÓ availability.
(3). Production of a limitless supply of cancer killing CAR-T cells, using proprietary differentiation and activation of iPSCs to create fully functional T cells engineered to contain the selected CAR and T cell receptor (TCR) genes.

In May 2018, Mesoblast Limited (Nasdaq:MESO) and Cartherics partners to develop allogeneic Çoff-the-shelf CAR-T cells armed with multiple targeting receptors for use in solid cancers with initial targets are relapsed ovarian and gastric cancers. Mesoblast and Cartherics will jointly own the intellectual property produced using their combined technologies.
The program will be funded by A$12.6 Mn ($US9.6 Mn) in direct and in-kind contributions from collaborators in the Australian Governments Cooperative Research Centres Program (CRC-P), including Cartherics, Monash University, Hudson Institute of Medical Research and Cell Therapies Pty Ltd.

Cartherics has committed funding of AU$5 Million under a Series A financing round and a further AU$3.7 Million under a Series B financing round. It is seeking to increase its total funds available to AU$10 Million through a Series C financing round.